

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Follow-up data from the Phase III KEYNOTE-048 trial evaluating pembrolizumab alone or with chemotherapy versus the EXTREME regimen revealed which of the following results?**
 - a. Survival advantage with pembrolizumab monotherapy but not with pembrolizumab/chemotherapy
 - b. Survival advantage with pembrolizumab/chemotherapy but not with pembrolizumab alone
 - c. Survival advantage both with pembrolizumab monotherapy and with pembrolizumab/chemotherapy**
 - d. No survival benefit with pembrolizumab monotherapy or pembrolizumab/chemotherapy
- 2. The JUPITER-02 study reported increased efficacy of which of the following agents when combined with standard gemcitabine/cisplatin therapy for patients with recurrent or metastatic nasopharyngeal cancer?**
 - a. Larotrectinib
 - b. Toripalimab**
 - c. Paclitaxel
 - d. Trastuzumab
- 3. Which of the following fusion mutations is the pathognomonic finding for secretory carcinomas?**
 - a. KIF5B-RET
 - b. EML4-ALK
 - c. NTRK- ETV6**
 - d. FGFR3-TACC3
- 4. Which of the following drug types best describes the mechanism of action of the FDA-approved agents entrectinib and larotrectinib in the treatment of advanced secretory carcinomas with NTRK gene fusions?**
 - a. Tyrosine kinase inhibitor**
 - b. Bispecific antibody
 - c. PI3K inhibitor
 - d. BTK (Bruton tyrosine kinase) inhibitor